Gene, Gene Sequencing and Immune Response - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Gene

Gene Sequencing

Immune Response

Takeda grows in gene therapies again with $2bn Code Bio deal

pharmaphorum

FEBRUARY 23, 2022

Takeda has forged another alliance as it continues a push into gene therapy, agreeing a deal worth up to $2 billion with Code Biotherapeutics for opt-in rights to four candidates for rare diseases. The post Takeda grows in gene therapies again with $2bn Code Bio deal appeared first on. Last October it signed a $3.6 billion-plus.

Gene Therapy

Gene Therapy Gene Gene Sequencing Immune Response

Medicago, GSK’s plant-made COVID jab clears phase 2

pharmaphorum

MAY 18, 2021

.” The interim phase 2 results show that two doses of the plant-derived jab stimulated neutralising antibody levels that are around 10 times higher than those in a panel of sera from patients recovering from COVID-19, with a similar response seen in adults and the elderly.

Vaccination

Vaccination Vaccine Immune Response Gene Sequencing

Zynteglo halt re-ignites viral vector safety concerns; analysts

pharmaphorum

FEBRUARY 22, 2021

Bluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of cancer were seen in a clinical trial could see fears over the safety of viral vectors used to deliver gene therapies resurface. . million in Europe.

Gene Therapy

Gene Therapy Gene Gene Sequencing Gene Expression

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Takeda grows in gene therapies again with $2bn Code Bio deal

Medicago, GSK’s plant-made COVID jab clears phase 2

Zynteglo halt re-ignites viral vector safety concerns; analysts

Webinars

Stay Connected